Prawo i regulacje · 24/06/2022

FDA Finalizes Schedule for New ADHD Medication Serdexmethylphenidate

The US Food and Drug Administration has finalized a rule placing serdexmethylphenidate, a new medication for attention deficit hyperactivity disorder (ADHD), in Schedule IV of the Controlled Substances Act, following an interim final rule published in 2021.